Published On: Mon, May 17th, 2021

Shilpa Medicare partners with Dr. Reddy’s for production of Sputnik V

Tagged with: | | | | | | | | |

Shilpa , through its fully-owned subsidiary , has signed a three-year agreement with Dr. Reddy’s Laboratories for the production and supply of the for .

The company will undertake production at its biologics research and development cum manufacturing center at Dharwad in Karnataka.

Shilpa Medicare said that the targeted production of the dual vector Sputnik V Covid-19 vaccine for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production.

Shilpa Medicare partners with Dr. Reddy's Laboratories for production of Sputnik V Covid-19 vaccine.

Shilpa Medicare partners with Dr. Reddy’s Laboratories for production of Sputnik V Covid-19 vaccine. Photo courtesy of The Russian Direct Investment Fund.

Dr. Reddy’s Laboratories, which has partnered with the Russian Direct Investment Fund (RDIF) for clinical development of the Sputnik V vaccine and has distribution rights in India and other geographies.

The Indian pharma major will enable the transfer of the Sputnik V vaccine technology to Shilpa Biologicals. The latter will handle the manufacture of the Russian Covid vaccine, while Dr. Reddy’s Laboratories will take care of its distribution/marketing in its marketing territories.

The parties are also said to be exploring the option of manufacturing Sputnik Light, a single dose version of the Sputnik V vaccine in the near future.

Last week, Dr. Reddy’s Laboratories launched the Sputnik V Covid vaccine in India at a price of around INR 995 per .

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Recent Posts